Novo Nordisk Plans NovoLog Mix Marketing Around Glycemic Control Benefits
This article was originally published in The Pink Sheet Daily
Executive Summary
Dosing may be less convenient, but pre-mixed product provides better diabetes control than once-daily injections like Sanofi-Aventis' Lantus, Novo Nordisk CEO Sorensen maintains. The company expects approval of its long-acting insulin Levemir in the third quarter of 2005.